These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21502342)

  • 1. Can Health Canada protect Canadians from unsafe drugs?
    Hébert PC; Stanbrook MB; MacDonald N; Flegel K; Coutts J; MacLeod S
    CMAJ; 2011 Jul; 183(10):1125-6. PubMed ID: 21502342
    [No Abstract]   [Full Text] [Related]  

  • 2. Health Canada's Progressive Licensing Framework.
    Yeates N; Lee DK; Maher M
    CMAJ; 2007 Jun; 176(13):1845-7. PubMed ID: 17576983
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1294,6. PubMed ID: 10683122
    [No Abstract]   [Full Text] [Related]  

  • 4. Progressive drug licensing: an opportunity to achieve transparency and accountability?
    Wright JM
    CMAJ; 2007 Jun; 176(13):1848-9. PubMed ID: 17576984
    [No Abstract]   [Full Text] [Related]  

  • 5. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 6. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulatory advice on evaluation of the proarrhythmic potential of drugs.
    Stockbridge N; Throckmorton DC
    J Electrocardiol; 2004; 37 Suppl():40-1. PubMed ID: 15534791
    [No Abstract]   [Full Text] [Related]  

  • 8. Progressive licensing needs progressive open debate.
    Hébert PC; Stanbrook M; Sibbald B; Flegel K; MacDonald N; Attaran A
    CMAJ; 2007 Jun; 176(13):1801, 1803. PubMed ID: 17576971
    [No Abstract]   [Full Text] [Related]  

  • 9. Health authorities and drug utilization studies.
    Garcia Alonso F; Scott AI; Stika L; Westerholm B
    WHO Reg Publ Eur Ser; 1993; 45():147-67. PubMed ID: 8442843
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug withdrawals from the Canadian market for safety reasons, 1963-2004.
    Lexchin J
    CMAJ; 2005 Mar; 172(6):765-7. PubMed ID: 15767610
    [No Abstract]   [Full Text] [Related]  

  • 11. CIHR appointment.
    Roos NP; Baird P
    CMAJ; 2010 Jan; 182(1):65. PubMed ID: 20064969
    [No Abstract]   [Full Text] [Related]  

  • 12. A new era in drug regulation?
    Dresser R
    Hastings Cent Rep; 2005; 35(3):10-1. PubMed ID: 16092391
    [No Abstract]   [Full Text] [Related]  

  • 13. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA; Brushwood DB
    J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter to the ISPE commentary editor.
    Rawson NS
    Pharmacoepidemiol Drug Saf; 2003; 12(1):71-2. PubMed ID: 12616851
    [No Abstract]   [Full Text] [Related]  

  • 15. Mandatory pharmacovigilance.
    Maksymowych WP
    CMAJ; 2003 Mar; 168(6):672; discussion 672-3. PubMed ID: 12642413
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacovigilance in Europe and North America: divergent approaches.
    Wiktorowicz M; Lexchin J; Moscou K
    Soc Sci Med; 2012 Jul; 75(1):165-70. PubMed ID: 22521677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of potency of Hepatitis B immunoglobulin marketed in India to evaluate the manufacturer's production consistency: Role of National Control Laboratory.
    Meena J; Sood S; Rani N; Bisht R; Kiran M; Chhabra R; Singh S; Chand S
    Biologicals; 2019 May; 59():72-73. PubMed ID: 30917901
    [No Abstract]   [Full Text] [Related]  

  • 18. [Drug regulation in Spain].
    Rubio Terrés C
    Med Clin (Barc); 1992 May; 98(19):741-8. PubMed ID: 1608280
    [No Abstract]   [Full Text] [Related]  

  • 19. Health Canada targets postmarket surveillance of drugs.
    Sibbald B
    CMAJ; 2002 Jun; 166(12):1580. PubMed ID: 12074132
    [No Abstract]   [Full Text] [Related]  

  • 20. Regulatory evaluation of efficacy and safety of new drugs in Thailand.
    Hutangkabodee S; Krisanaphan C; Reggi V; Figueras A; Bonati M
    J Med Assoc Thai; 2004 Sep; 87(9):1135-6. PubMed ID: 15516020
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.